- NCIt
- C4925
Loading cancer entity…
Loading cancer entity…
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04715191 |
| Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors |
| recruiting |
| Phase 1 |
| 24 |
| Baylor College of MedicineOTHER |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT07218913 | Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors | recruiting | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00387920 | Sunitinib in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 2 | Jan 28, 2014 | clinicaltrials |
| NCT00929903 | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00077454 | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00281944 | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials